Nivolumab: observed
229 studies: patients on it are followed, or it is given outside a trial. Page 2 of 3. Open to participants first (50), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial CarcinomaActive, not recruitingNCT05779592Report a problem
- Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung CancerCompletedNCT05740501Report a problem
- Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05714371Report a problem
- Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNCT05611229Report a problem
- A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung CancerCompletedNCT05599685Report a problem
- Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination ImmunotherapyCompletedNCT05579847Report a problem
- CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving NivolumabStatus unknownNCT05564923Report a problem
- A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyCompletedNCT05432622Report a problem
- Immunological Variables Associated to ICI Toxicity in Cancer PatientsStatus unknownNCT05429866Phase 2Report a problem
- A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)CompletedNCT05420909Report a problem
- Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic CancerCompletedNCT05380336Report a problem
- A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsCompletedNCT05361434Report a problem
- A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric CancerCompletedNCT05334719Report a problem
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Report a problem
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Report a problem
- A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)CompletedNCT05324436Report a problem
- Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)CompletedNCT05308966Report a problem
- Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative DeliriumCompletedNCT05273827Report a problem
- MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal CancerCompletedNCT05189171Report a problem
- Expanded Access for Fixed-Dose Combination of Nivolumab Plus RelatlimabNo longer availableNCT05170685Report a problem
- A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And PortugalCompletedNCT05168436Report a problem
- A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric CancerActive, not recruitingNCT05165264Report a problem
- A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanActive, not recruitingNCT05161325Report a problem
- A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in EuropeCompletedNCT05123950Report a problem
- A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)CompletedNCT05068609Report a problem
- A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and CyprusCompletedNCT05034926Report a problem
- Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932Report a problem
- A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United KingdomCompletedNCT04936399Report a problem
- The Prospective Non-randomized Case-control Study From Real-world Lung Cancer PatientsCompletedNCT04909164Report a problem
- Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint InhibitorsCompletedNCT04898751Report a problem
- Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)Status unknownNCT04891055Report a problem
- Energy for LymphocytesCompletedNCT04879316Report a problem
- Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid TumorsStatus unknownNCT04860076Report a problem
- Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung CancerCompletedNCT04858204Report a problem
- A Study to Assess Safety of Nivolumab in Routine Oncology Practice in ChinaCompletedNCT04825873Report a problem
- A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04794010Report a problem
- Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by ImmunotherapyCompletedNCT04775446Report a problem
- Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal CancerStatus unknownNCT04771715Report a problem
- Real-world Data of Nivolumab in Pre-treated NSCLCCompletedNCT04713462Report a problem
- Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent ChemoradiotherapyCompletedNCT04654234Report a problem
- Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284Report a problem
- Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012Report a problem
- Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)CompletedNCT04606940Report a problem
- Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.Status unknownNCT04595734Report a problem
- A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in FranceActive, not recruitingNCT04550247Report a problem
- A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyCompletedNCT04500535Report a problem
- Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/MelanomaCompletedNCT04490564Report a problem
- BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 DrugsTerminatedNCT04473027Report a problem
- Thyroid Dysfunction and Nivolumab Reponse in NSCLCCompletedNCT04470440Report a problem
- QUantitative Assessment of Swallowing After Radiation (QUASAR)Status unknownNCT04359199Report a problem
- Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806Report a problem
- A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With ChemotherapyStatus unknownNCT04306042Report a problem
- Immune Related-adverse Events in Patients Receiving Immune Checkpoint InhibitorsStatus unknownNCT04268368Report a problem
- Polish Microbiome MapStatus unknownNCT04169867Report a problem
- A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab TherapyCompletedNCT04161911Report a problem
- A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT04161781Report a problem
- CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional StudyTerminatedNCT04147143Report a problem
- An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in AustraliaCompletedNCT04146324Report a problem
- Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064Report a problem
- AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.Status unknownNCT04145232Report a problem
- BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsStatus unknownNCT04136470Report a problem
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410Report a problem
- Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT04106349Report a problem
- Early Response Evaluation in NSCLC Patients Treated With ImmunotherapyTerminatedNCT04082988Not applicableReport a problem
- A Study of Nivolumab in Patients With Head and Neck Cancer.CompletedNCT04050761Report a problem
- A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in JapanCompletedNCT04043975Report a problem
- Real World Study of Four PD-1 Agents in ChinaStatus unknownNCT03966456Report a problem
- WGA in Platinum-refractory HNSCC Underwent NivolumabStatus unknownNCT03917537Report a problem
- Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve EfficacyCompletedNCT03891485Report a problem
- Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)CompletedNCT03868046Report a problem
- Memory Phenotype and PD-1 Inhibition Response in Oral CancerTerminatedNCT03862066Report a problem
- A Study To See Why Patients Agree To or Decline To Have Treatment After SurgeryCompletedNCT03843593Report a problem
- The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03816657Report a problem
- A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With NivolumabCompletedNCT03804554Report a problem
- A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedCompletedNCT03771859Report a problem
- A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USCompletedNCT03732560Report a problem
- A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint InhibitorsActive, not recruitingNCT03695952Report a problem
- Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip PlatformStatus unknownNCT03692442Report a problem
- A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has SpreadCompletedNCT03663946Report a problem
- Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell CarcinomaStatus unknownNCT03652142Report a problem
- Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingNCT03647878Report a problem
- BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)Status unknownNCT03628859Report a problem
- Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has SpreadCompletedNCT03569436Report a problem
- Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer ParticipantsCompletedNCT03568435Report a problem
- 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCCompletedNCT03564197Not applicableReport a problem
- Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck CancerTerminatedNCT03539198Report a problem
- PD-L1 PET Imaging in Melanoma PatientsCompletedNCT03520634Not applicableReport a problem
- Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced MelanomaCompletedNCT03504696Report a problem
- Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReActionCompletedNCT03492242Report a problem
- A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsCompletedNCT03486119Report a problem
- Improved Therapy Response Assessment in Metastatic Brain TumorsActive, not recruitingNCT03458455Report a problem
- Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerCompletedNCT03455452Report a problem
- Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint InhibitionCompletedNCT03453892Report a problem
- Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination TherapyCompletedNCT03438279Report a problem
- Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung CancerCompletedNCT03433534Report a problem
- Biomarkers of Immune-Related ToxicityActive, not recruitingNCT03409016Report a problem
- Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse ReactionsCompletedNCT03387540Report a problem
- Observational Study for Lung Cancer Patients Treated With NivolumabCompletedNCT03382496Report a problem
- Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic MelanomaCompletedNCT03356470Report a problem
- TNF in Melanoma Patients Treated With ImmunotherapyCompletedNCT03348891Not applicableReport a problem